Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.
Piha-Paul S, Sachdev J, Barve M, LoRusso P, Szmulewitz R, Patel S, McKee M, Wolff J, Hu B, Sood A, Chen X, Wilson S, O'Neil B. Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors. Journal Of Clinical Oncology 2018, 36: 2510-2510. DOI: 10.1200/jco.2018.36.15_suppl.2510.Peer-Reviewed Original Research